Even after this indictment, however, the 2004 British Hypertension Society (BHS) guidelines (4) put betablockers alongside angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) as initial therapy for hypertensive patients under age 55 years and for nonblack patients. The 2004 BHS guidelines did, however, hedge their position, stating that according to their AB/CD algorithm, either an ACEI or an ARB (A) or a beta-blocker (B) should be chosen for younger and nonblack patients whereas either a calcium-channel blocker (C) or a diuretic (D) should be chosen for patients who are over age 55 years or black, but the algorithm does place the "B" in brackets. The report says, "the reason is to emphasize the fact that recent trials have reported an increase in onset of diabetes in patients treated with B or D drugs compared with A or C drugs, especially when B and D are combined. We advise caution when using BϩD in patients at especially high risk of developing diabetes as for example, patients with a strong family history of type 2 diabetes, obesity, impaired glucose tolerance, features of metabolic syndrome or of South Asian and African-Caribbean descent" (4) .
Note that the warning did not relate to the lesser benefit of beta-blockers in general, only to their propensity to bring out diabetes.
The British did amend their position in a statement on their website on June 28, 2006, providing a new algorithm without a B (beta-blocker) anywhere to be found and including the statement that "beta-blockers are no longer preferred as a routine initial therapy for hypertension" (5) .
This good advice, however, did not get through to the writers of the 2007 European Society of Hypertension and European Society of Cardiology guidelines (6). They stated: "Beta-blockers may still be considered an option for initial and subsequent antihypertensive treatment strategies. Because they favor an increase in weight, have adverse effects on lipid metabolism and increase (compared with other drugs) the incidence of new-onset diabetes, they should not be preferred, however, in hypertensives with multiple metabolic risk factors including the metabolic syndrome. . ." (6).
The Swedish Explosion
Messerli et al. (7) said it again in 2007, in this Journal, adding a litany of side effects from beta-blockers, including: 1) precipitation of diabetes; 2) little effect on regression of left ventricular hypertrophy; 3) likely failure to improve endothelial function; 4) weight gain; and 5) decrease in exercise endurance.
To emphasize their position, they added: "For every myocardial infarction or stroke prevented in the Medical Research Council study (8) , 3 patients treated with atenolol withdrew from the study secondary to impotence and another 7 withdrew because of fatigue" (7) . the world these days, it took the Swedes to lower the curtain.
Rather surprisingly, in view of the prior analyses by Messerli et al. (1) showing equal protection against stroke by beta-blockers, the problem shown by the Swedish metaanalyses was lesser protection against strokes by betablockers.
The Additional Blow
The paper by Bangalore et al. (11) in this issue of the Journal adds another post-mortem explanation for the fall of betablockers, showing higher mortality associated with the slower heart rate they induce. Of interest, the fall in pulse rate is an obvious mechanism for the higher central blood pressure with beta-blocker-based therapy noted by Williams et al. (12) in the CAFE (Conduit Artery Function Evaluation) study. With this addition to the evidence, beta-blockers will surely remain as indicated for heart failure, for after myocardial infarction, and for tachyarrhythmias, but no longer for hypertension in the absence of these compelling indications.
